Von Willebrand Disease: Symptoms, Diagnosis, Treatment & Bleeding Care

VWD almost always manifests as mucocutaneous bleeding—menorrhagia, prolonged bleeding after cuts or dental work, epistaxis, gingival oozing, and easy bruising. Postoperative or postpartum bleeding may be the first unmasking event. Unlike disorders of secondary haemostasis alone, joint deep haemarthroses are uncommon except when FVIII falls substantially in type 3.

Typical cues

• Heavy cyclical bleeding meeting published menorrhagia thresholds with iron-refractory fatigue.
• Prolonged bleeding after scaling, extraction, tonsillectomy, or central line insertion.
• Recurrent ecchymoses without trauma sufficient to explain size.

Atypical or “later-life” presentations

• Acquired von Willebrand syndrome in aortic stenosis, ventricular assist devices, hypothyroidism, or lymphoproliferative disease—bleeding emerges without childhood history.
• Patients on heparin or warfarin where drug effect and VWD overlap—interpret INR cautiously and avoid attributing all bleeding to anticoagulation alone.

Inherited VWD follows autosomal dominant inheritance for most type 1 and many type 2 variants, while type 3 often reflects biallelic or compound inheritance producing very low VWF. Molecular subtype determines whether multimers are absent, qualitatively abnormal, or whether hyper-adhesive VWF consumes platelets (type 2B).

Modulators that change measured VWF

• ABO blood group (non-O lower baseline VWF—interpret against reference ranges).
• Pregnancy, oestrogen therapy, inflammation, and stress can transiently raise VWF—repeat testing may be needed outside acute-phase physiology.
• Medications that impair platelet function or potentiate bleeding (NSAIDs, SSRIs, anticoagulants) unmask mild VWD.

Diagnosis begins with a structured bleeding history. The ISTH bleeding assessment tool standardises which bleeding symptoms count as significant for adults and children, improving inter-clinician reproducibility before ordering VWF laboratory panels (antigen, activity, and FVIII as a bundle). Many centres therefore treat a positive bleeding-score as the gate for formal laboratory phenotyping rather than isolated clinician impression. Laboratory work-up pairs VWF antigen with VWF activity (ristocetin cofactor or functionally equivalent assay), FVIII, and multimeric analysis when ratios suggest type 2 disease.

Laboratory cascade (nurse-facing overview)

• Screening: CBC (ensure thrombocytopenia is not the primary driver), APTT (may be normal or prolonged), group & screen.
• Diagnosis: VWF antigen, VWF activity, FVIII; calculate activity-to-antigen ratio to flag qualitative disease.
• Phenotyping: Multimer gel, ristocetin-induced platelet aggregation where available, and targeted genotyping coordinated by haematology.

Repeat testing at least once outside acute illness is common practice because VWF is an acute-phase reactant—misclassification drops when results are confirmed on a stable outpatient sample.

1. Bleeding screen positive (ISTH tool): Refer to haematology and schedule VWF antigen, activity, and FVIII on a non-acute sample where feasible.
2. Ratio <0.7 or high clinical suspicion: Add multimer studies before planning elective DDAVP cover—avoid empiric DDAVP in unclassified type 2B risk.
3. DDAVP trial: Measure VWF activity and FVIII at baseline and 60–120 minutes (local protocol) and define whether levels reach haemostatic targets for the planned procedure.
4. Procedure day: Administer prescribed DDAVP or VWF/FVIII concentrate with infusion monitoring; co-administer tranexamic acid only if ordered.
5. Failure to control bleeding: Escalate to haematology + major haemorrhage pathway; expect second-line concentrates or adjunctive agents.

• Platelet disorders and Bernard–Soulier–type qualitative defects—abnormal platelet function testing or low ristocetin cofactor may overlap; haematology distinguishes.
• Mild haemophilia A when FVIII is disproportionately low—FVIII:C sequencing may be required.
• Liver disease, renal failure, or DIC lowering multiple factors—not isolated VWF patterns.
• Anticoagulant effect alone—review agents and reversal options alongside VWF testing.

First-line strategies

• DDAVP (IV, subcutaneous, or intranasal depending on formulation availability) for responsive type 1 disease—always paired with sodium and fluid surveillance.
• Tranexamic acid for mucosal bleeding and many dental procedures when not contraindicated—follow local dosing.
• VWF-containing FVIII concentrates for non-responders, many type 2 variants, type 3, major surgery, or when DDAVP trials fail to reach target peaks.

Adjuncts for menorrhagia

Hormonal therapies (combined hormonal contraception, levonorgestrel intrauterine systems) frequently reduce menstrual blood loss and are commonly co-prescribed with haematology input—document effect on haemoglobin and symptoms at 8–12 weeks.

Special populations

Pregnancy and labour require multidisciplinary planning because VWF rises but may still be inadequate in severe disease; postpartum VWF falls rapidly—observe lochia, fundal tone, and haemoglobin closely for 72 hours minimum. Children need weight-based dosing and careful fluid prescribing around DDAVP.

• Hyponatraemic encephalopathy from repeated DDAVP without fluid restriction.
• Thrombotic risk with high-purity VWF concentrates in certain comorbidities—monitor per product monograph and haematology advice.
• Inhibitors to FVIII (rare in true VWD but reported)—suspect when expected recovery levels are not achieved.
• Iron deficiency and fatigue from chronic menorrhagia—track ferritin response to oral iron.

Prevention is procedural: preoperative haematology review, medication reconciliation, avoidance of unnecessary NSAIDs, dental coordination with antifibrinolytics, and patient-held emergency cards listing VWD type, DDAVP responsiveness, and concentrate allergies.

With accurate phenotyping and access to DDAVP or concentrates, most people with type 1 VWD experience near-normal surgical bleeding risk. Type 3 and complicated type 2 disease require lifelong specialist partnership but should still reach safe haemostasis when plans are followed.

Shift nurses add value by timestamping bleeding episodes, capturing orthostatic vitals, ensuring pre- and post-infusion labs reach the chart, and coaching patients to avoid hidden NSAIDs in cold remedies. DDAVP stewardship means pairing each dose with sodium surveillance, fluid limits, and prescriber-defined stop rules rather than ad-hoc repeats. When patients carry a smartphone photograph of their haemostasis plan, photograph it into the legal record with consent—reduces transcription errors during emergency re-presentations.

• Pre-infusion: allergies, weight, pregnancy status, baseline sodium, FVIII/VWF labs drawn if ordered.
• During DDAVP: blood pressure, urine output, conscious level, strict fluid balance, scheduled sodium rechecks.
• During concentrate: observation per the same blood-product infusion safety policy used for standard transfusion care—vitals per protocol first 15–30 minutes, then intervals; pause for urticaria or rigors and notify prescriber.
• Post-procedure: surgical site checks, drain outputs, serial haemoglobin, patient education on delayed bleeding signs.

• Syncope, tachycardia out of proportion to pain, or hypotension with bleeding.
• Airway compromise from oropharyngeal haemorrhage.
• Head injury while anticoagulated or with severe headache and vomiting.
• Heavy vaginal bleeding with clots and signs of shock.

Worsening tachycardia, narrowing pulse pressure, rising lactate, falling haemoglobin without overt external loss, or new confusion after DDAVP may signal hyponatraemia or concealed haemorrhage—repeat focused exam, escalate to senior medical staff, and arrange urgent sodium and group & screen.

Pre-treatment

Verify the haemostasis plan matches the procedure risk tier; ensure pharmacy has released the correct plasma-derived product (brand, lot) when multiple VWF concentrates exist.

Post-treatment

Continue scheduled observations until the haematologist clears step-down; reinforce dental and surgical follow-up appointments.

Education & evaluation

Teach patients to disclose VWD before acupuncture, tattooing, or new antiplatelet therapy; evaluate understanding with teach-back and document who received counselling.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, and matrix matching on the topic of ISTH bleeding-score triggers, VWF activity versus antigen interpretation, DDAVP stewardship, concentrate selection, and perioperative safety—mirroring Clinical Judgment Measurement Model reasoning from cue recognition through evaluation of outcomes.